Study of Fenretinide in the Treatment of Geographic Atrophy Associated With Dry Age-Related Macular Degeneration
NCT ID: NCT00429936
Last Updated: 2010-06-22
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2
245 participants
INTERVENTIONAL
2006-12-31
2010-05-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Study to Evaluate the Efficacy and Safety of Oral CT1812 in Participants With Geographic Atrophy (GA) Secondary to Dry Age-Related Macular Degeneration (AMD).
NCT05893537
Intravitreal Injections of Sirolimus in the Treatment of Geographic Atrophy
NCT01675947
Pilot Study of the Evaluation of Subconjunctival Sirolimus in the Treatment of Bilateral GA Associated With AMD
NCT00766649
Clinical Study to Investigate Safety and Efficacy of GSK933776 in Adult Patients With Geographic Atrophy Secondary to Age-related Macular Degeneration
NCT01342926
Phase 2 Study of ADX-038 in Participants With Geographic Atrophy
NCT06990269
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
100 mg fenretinide softgel capsules
Three (3) 100-mg fenretinide softgel capsules
Fenretinide
Once daily 30 minutes after the evening meal for 24 months
Fenretinide and placebo softgel capsules
One (1) 100-mg fenretinide softgel capsule and two (2) placebo softgel capsules
Fenretinide
Once daily 30 minutes after the evening meal for 24 months
Placebo softgel capsules
Three (3) placebo softgel capsules
Fenretinide
Once daily 30 minutes after the evening meal for 24 months
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Fenretinide
Once daily 30 minutes after the evening meal for 24 months
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* must have GA from AMD in one or both eyes
Exclusion Criteria
50 Years
89 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
ReVision Therapeutics, Inc.
OTHER
Sirion Therapeutics, Inc.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
ReVision Therapeutics, Inc.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Roger Vogel, MD
Role: STUDY_DIRECTOR
ReVision Therapeutics Advisor
References
Explore related publications, articles, or registry entries linked to this study.
Yeong JL, Loveman E, Colquitt JL, Royle P, Waugh N, Lois N. Visual cycle modulators versus placebo or observation for the prevention and treatment of geographic atrophy due to age-related macular degeneration. Cochrane Database Syst Rev. 2020 Dec 17;12(12):CD013154. doi: 10.1002/14651858.CD013154.pub2.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
SRFR-001
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.